# Clinical Trials Data EGFR - Document 117

# Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01688713

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histological or cytologic diagnosis of NSCLC\n\* Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment.\n\* Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment.\n\* ECOG performance status 0-2\n\* Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)\n\* Expected survival of greater than 3 months\n\* Age: 18-75 years\n\* The patients with key organs maintenance of basic function: Hemoglobin \u2265 9g/dL, White Blood Cell \u2265 3\u00d7109/L, Neutrophil count \u2265 1.5\u00d7109/L, platelets \u2265 80\u00d7109/L, total bilirubin \\< 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) \\< 2.5 of the upper normal values, the serum creatinine \\< 1.5 times of the upper normal values\n\* Signed informed consent document on file.\n\nExclusion Criteria:\n\n\* Brain metastasis without local treatment before\n\* Patients without the treatment of Icotinib before or the therapeutic time less than 3 months\n\* More than 3 extracranial organs have metastatic lesions\n\* The patient with other type malignant tumors before\n\* The patient with fertility capacity, but without contraceptive application",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an EGFR gene mutation would be eligible for the trial, assuming they meet all other inclusion criteria and do not fall under any of the exclusion criteria.  
  
The inclusion criteria specifically state: "Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment (WBRT and/or SRS) combined with Icotinib treatment." This suggests that having an EGFR mutation is a factor that can make a patient eligible for the trial, provided other conditions are also satisfied.  
  
To ensure eligibility, the patient must also meet other requirements, such as having had disease progression after specified local treatments combined with Icotinib, having a certain performance status, having adequate organ function, etc. Additionally, they must not be excluded based on criteria such as having untreated brain metastasis, insufficient duration of Icotinib treatment prior to the trial, excessive metastatic disease, or other factors listed under the exclusion criteria.